The new study, which was funded by Eli Lilly, enrolled about 800 people who had obesity or were overweight with a weight-related health complication but not diabetes
The GLP-1 user has a never-before-seen unique profile
Thus, the significant increase in levels of 3-NT observed in the autism cerebellum and BA22 was not unexpected and is consistent with elevated superoxide production and aconitase inactivation
However, if you dont increase your dose, you may not lose more than 2% of your starting body weight
To stop them, stick to a low-fiber, low-sulfur diet (like chicken and rice) for 24-48 hours
The lawsuit follows growing concern sparked by a July 2024 Harvard study linking semaglutide drugs like Ozempic to NAION, with more evidence emerging in January 2025 and regulatory attention from European agencies